Lung cancer that harbors an HER2 Mutation: Epidemiologic characteristics and therapeutic perspectives

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1997-2003

  Mazières, Julien ^a   Peters, Solange ⁿ   Lepage, Benoit ^b   Cortot, Alexis B ^d   Barlesi, Fabrice ^e   Beau Faller, Michéle ^f   Besse, Benjamin ^g   Blons, Hélène ⁱ   Mansuet Lupo, Audrey ^h   Urban, Thierry ^l   Moro Sibilot, Denis ^m   Dansin, Eric ^e   Chouaid, Christos ^j   Wislez, Marie ^k   Diebold, Joachim ^o   Felip, Enriqueta ^p,q   Rouquette, Isabelle ^c   Milia, Julie D ^a   Gautschi, Oliver ^o  

^a SERVICE DE PNEUMOLOGIE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CHU RANGUEIL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f HÔPITAL NORD   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j Nuclear Medicine Department   (France)

^k HÔPITAL SAINT ANTOINE   (France)

^l HÔPITAL TENON   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ HÔPITAL MICHALLON   (France)

^o LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^p LUZERNER KANTONSSPITAL   (Switzerland)

^q HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; LAPATINIB; MASITINIB; PACLITAXEL; TRASTUZUMAB; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE COURSE; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT RESPONSE; ADENOCARCINOMA; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; FLUORESCENCE IN SITU HYBRIDIZATION; FRANCE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SPAIN; SWITZERLAND; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTAGENESIS, INSERTIONAL; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SPAIN; SWITZERLAND; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880661427     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.6095     Document Type: Article

References (23)

1. Pao W, Hutchinson KE: Chipping away at the lung cancer genome. Nat Med 18:349-351, 2012
2. Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838-5847, 2009
3. Perera SA, Li D, Shimamura T, et al: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106:474-479, 2009
4. Shimamura T, Ji H, Minami Y, et al: Nonsmall-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66:6487-6491, 2006
5. Rouquette I, Lauwers-Cances V, Allera C, et al: Characteristics of lung cancer in women: Importance of hormonal and growth factors. Lung Cancer 76:280-285, 2012
6. Menard S, Casalini P, Campiglio M, et al: HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 12:S15-S19, 2001 (suppl 1)
7. Heinmoller P, Gross C, Beyser K, et al: HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 9:5238-5243, 2003
8. Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
9. Buttitta F, Barassi F, Fresu G, et al: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 119:2586-2591, 2006
10. Pellegrini C, Falleni M, Marchetti A, et al: HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9:3645-3652, 2003
11. Arcila ME, Chaft JE, Nafa K, et al: Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18:4910-4918, 2012
12. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005
13. Tomizawa K, Suda K, Onozato R, et al: Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74:139-144, 2011
14. Arteaga CL, Sliwkowski MX, Osborne CK, et al: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32, 2012
15. Gatzemeier U, Groth G, Butts C, et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-smallcell lung cancer. Ann Oncol 15:19-27, 2004
16. Lara PN Jr, Laptalo L, Longmate J, et al: Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: A California Cancer Consortium screening and phase II trial. Clin Lung Cancer 5:231-236, 2004
17. De Greve J, Teugels E, Geers C, et al: Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76:123-127, 2012
18. Cappuzzo F, Bemis L, Varella-Garcia M: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354:2619-2621, 2006
19. Travis WD, Brambilla E, Noguchi M, et al: International association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
20. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
21. Li C, Sun Y, Fang R, et al: Lung adenocarcinomas with HER2-Activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol 7:85-89, 2012
22. Liu L, Shao X, Gao W, et al: The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-Analysis of published data. J Thorac Oncol 5:1922-1932, 2010
23. Ross HJ, Blumenschein GR Jr, Aisner J, et al: Randomized phase II multicenter trial of two schedules of lapatinib as first-or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16:1938-1949, 2010